Significant Progress in Cancer Treatment with Deltacel-01
Kiromic BioPharma, Inc. (OTCQB: KRBP) is making remarkable strides with its Deltacel-01 Phase 1 clinical trial, aimed at treating stage 4 metastatic non-small cell lung cancer (NSCLC). Following an eight-month follow-up of the fourth patient, the company reported a notable 32% decrease in tumor volume, showcasing the potential of its innovative Gamma Delta T-cell (GDT) therapy.
Patient Results Deliver Hope
The results from the fourth patient’s post-treatment assessment indicate a significant reduction in tumor size, marking a critical milestone in the ongoing research. This patient is progressing favorably without displaying any negative side effects, which suggests a promising tolerability profile for Deltacel™.
Long-term Data from Patient #1
In the meantime, the first participant in the Deltacel-01 trial has shown stable disease status with no signs of disease progression. Earlier assessments had indicated a 27% decrease in their tumor size when compared to pre-treatment measurements. As of now, this patient’s progress has extended over 11 months, further supporting the therapeutic promise of this treatment without adverse effects.
Ongoing Developments in the Clinical Trial
Additionally, the Deltacel-01 protocol continues to produce encouraging outcomes, as evidenced by the seventh patient, who has successfully completed the treatment regimen and is tolerating the therapy well. Initial efficacy data for this individual is anticipated in early January, which could provide further insights into the therapy’s effectiveness.
New Patient Participation
Recently, the eighth patient has been enrolled in the Deltacel-01 clinical study, marking an exciting new phase for the ongoing trial. As more patients join the study, Kiromic BioPharma anticipates enriching their data pool and enhancing understanding of Deltacel™’s full potential.
A Message from Leadership
Pietro Bersani, Chief Executive Officer of Kiromic BioPharma, expressed optimism regarding the results: “The substantial tumor reduction we’ve seen in Patient #4 is indeed monumental. We are eager to unveil further results from the first and seventh patients in January and plan to enroll additional participants as we move into 2025.”
Expert Insights
Dr. Afshin Eli Gabayan, a medical oncologist and principal investigator at the Beverly Hills Cancer Center, shares his enthusiasm: “The remarkable 32% tumor reduction seen in the fourth patient treated with Deltacel is promising and could significantly enhance outcomes for those affected by advanced lung cancer.” This highlights the critical nature of clinical trials in advancing treatment options for patients who have not succeeded with conventional therapies.
About Deltacel-01
The Deltacel-01 clinical trial is an open-label Phase 1 study designed to evaluate the safety and tolerability of GDT infusions, alongside low-dose radiotherapy, for patients with stage 4 NSCLC. This comprehensive evaluation includes numerous metrics such as progression-free survival and overall response rates, affording researchers insight into the treatment's overall impact.
Deltacel™: A Future Potential
Deltacel™ (KB-GDT-01) represents Kiromic’s innovative approach to treating solid tumors. By utilizing donor-derived GDT cells, this investigational therapy aims to leverage the natural capability of GDT cells in targeting cancers, especially non-small cell lung cancer, which constitutes a large percentage of lung cancer cases. Its compelling preclinical results provide a foundation for its ongoing clinical evaluation.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is dedicated to transforming cancer treatment through its allogeneic cell therapy platform, which emphasizes the potent capabilities of Gamma Delta T-cells. By employing advanced artificial intelligence within its DIAMOND platform, Kiromic is positioned to revolutionize the landscape of immuno-oncology and is committed to innovative patient-centered solutions in Houston, Texas.
Frequently Asked Questions
What are the primary objectives of the Deltacel-01 trial?
The Deltacel-01 trial primarily aims to evaluate the safety and tolerability of Deltacel™ alongside low-dose radiotherapy in patients with stage 4 NSCLC.
How is the Deltacel therapy administered?
Deltacel therapy involves two intravenous infusions accompanied by four courses of localized radiation over a ten-day span.
What have the results been for the first patient enrolled?
The first patient has maintained stable disease, with a 27% reduction in tumor size and no signs of disease progression over 11 months.
When can we expect more results from the clinical trial?
Additional results from the trial, particularly for the first and seventh patients, are expected to be reported in January.
What is the significance of the 32% tumor reduction?
The reduction signifies meaningful efficacy of the Deltacel therapy, potentially marking a new avenue for improving outcomes in patients with advanced lung cancer.
